Latest Supply Agreements News

Genetic Signatures has locked in a 10-year supply deal with Denmark’s Hvidovre Hospital for its EasyScreen™ Pan-Enteric assay, marking a significant step in its European expansion. The agreement covers 28,000 tests in the first year with growth expected, leveraging the company’s proprietary 3base® technology to streamline complex gastrointestinal pathogen detection.

Echelon Resources' Palm Valley Joint Venture has locked in a gas supply agreement with the Northern Territory government, enabling drilling of two new wells to restore production capacity by mid-2026.

Amaero Ltd (ASX:3DA) has signed a Master Purchasing Agreement worth A$7.8 million for titanium alloy powders, underpinning plans to double production in FY2027 amid strong demand across multiple sectors.

Delorean Corporation has approved the Final Investment Decision for its 100% owned NSW1 Horsley Park Bioenergy Facility, supported by $30.5 million in grants. Construction is planned to start in Q3 2026, pending the securing of $31.6 million in additional funding.

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

Radiopharm Theranostics has secured a clinical supply agreement with Siemens Healthineers to manufacture and distribute RAD101, advancing its Phase 3 trial in the U.S. Interim Phase 2b data showed 90% concordance with MRI in detecting brain metastases.

Wellnex Life has extended its licensing and supply agreement with Haleon UK for soft gel liquid paracetamol products until March 2027, reinforcing its position in the global analgesics market.

Algorae Pharmaceuticals has reached a key regulatory milestone as the TGA accepts its initial registration dossier, paving the way for potential commercialisation of its generic medicines in Australia and New Zealand.

Metallium Limited’s US subsidiary has inked a decade-long off-take agreement with Indium Corporation, setting a firm commercial foundation for supplying critical metals like gallium and germanium recovered through innovative recycling technology.

State Gas Limited has decided against proceeding with the sale of its High Density Natural Gas Pilot Plant after failing to finalise terms, while its R&D tax incentive claim remains under extended review by the ATO.

Atomo Diagnostics stands to gain significantly as Lumos Diagnostics’ FebriDx test secures FDA CLIA waiver approval, vastly expanding its US market potential. This regulatory milestone triggers substantial contracted revenues and prompts Atomo to ramp up production.

Botanix Pharmaceuticals has successfully renegotiated its API supply agreement, deferring significant purchases to later years and strengthening its financial position ahead of Sofdra's market rollout.